Evidence map›Paper›PMID 40089478›Full record

ArticleNature communications2025

Caspase 9-induced apoptosis enables efficient fetal cell ablation and disease modeling.

Kenji Matsui, Masahito Watanabe, Shutaro Yamamoto, Shiho Kawagoe, Takumi Ikeda, Hinari Ohashi, Takafumi Kuroda, Nagisa Koda, Keita Morimoto, Yoshitaka Kinoshita and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Kenji MatsuiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0003-2897-2285
Masahito WatanabeMeiji University International Institute for Bio-Resource Research, Kanagawa, Japan.
Shutaro YamamotoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3061-1617
Shiho KawagoeDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Takumi IkedaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Hinari OhashiDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Takafumi KurodaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Nagisa KodaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Keita MorimotoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Yoshitaka KinoshitaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-6896-3407
Yuka InageDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-4874-4215
Yatsumu SaitoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Shohei FukunagaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-5905-2476
Toshinari FujimotoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0002-4178-8645
Susumu TajiriDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Kei MatsumotoDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Eiji KobayashiDepartment of Kidney Regenerative Medicine, The Jikei University School of Medicine, Tokyo, Japan.ORCID http://orcid.org/0000-0001-8617-3778
Takashi YokooDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. tyokoo@jikei.ac.jp.ORCID http://orcid.org/0000-0003-1838-7998
Shuichiro YamanakaDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. shu.yamanaka@jikei.ac.jp.ORCID http://orcid.org/0000-0002-4741-1005

Funding

Japan Agency for Medical Research and Development (AMED) JP22bm0704049Japan Agency for Medical Research and Development (AMED) JP24bm1123036Japan Agency for Medical Research and Development (AMED) JP24bm1223003MEXT | Japan Science and Technology Agency (JST) JPMJFR2011MEXT | Japan Society for the Promotion of Science (JSPS) JP19K17756MEXT | Japan Society for the Promotion of Science (JSPS) JP21K08288MEXT | Japan Society for the Promotion of Science (JSPS) JP23K07725MEXT | Japan Society for the Promotion of Science (JSPS) JP23K15255MEXT | Japan Society for the Promotion of Science (JSPS) JP24K11439
6 · The paper itself

Abstract

Fetal cell ablation models are crucial for studying congenital diseases, organ regeneration, and xenotransplantation. However, conventional knockout models offer limited control over disease severity, while conditional ablation models often require fetus-harming inducers. In the present study, we demonstrate that the inducible caspase 9 system enables precise targeting of fetal nephron progenitor cells in mice through the intrinsic apoptotic pathway. Using a safe, placenta-permeable inducer, this system facilitates specific, rapid, and efficient cell ablation. The system's temporal control allows precise adjustment of disease severity, generating reproducible models ranging from congenital kidney deficiency to severe chronic kidney disease. Cells with low expression levels of inducible caspase 9 and those in solid organs are less susceptible to apoptosis. However, this limitation can be overcome by inhibiting the X-linked inhibitor of apoptosis protein, thereby expanding the system's applicability. Additionally, this model provides a developmental environment suitable for chimeric kidney regeneration. This system advances understanding of induced cell death mechanisms, enhances pathological research tools, and supports therapeutic development in kidney disease and xenotransplantation applications.

Indexed as

ApoptosisCaspase 9AnimalsDisease Models, AnimalFemaleFetusHumansKidneyMiceMice, Inbred C57BLNephronsPregnancyRegenerationCaspase 9

Identifiers

PMID40089478
PMCPMC11910536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.